Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about MERCK & CO., INC.
06:46aMerck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine..
BU
01/27Merck & Co.'s Keytruda Wins EU Nod for Adjuvant Treatment of Kidney Cancer
MT
01/27Merck Gets EU Expanded OK for Keytruda in Some Kidney Cancer Patients
DJ
01/27Merck's Keytruda Gets EU Nod for Use as Adjuvant Therapy in Renal Cell Carcinoma
MT
01/27European Commission Approves Merck's KEYTRUDA« (pembrolizumab) as Adjuvant Therapy for ..
BU
01/25Merck & Co. Declares Q2 Dividend of $0.69, Payable April 7 to Shareholders of Record Ma..
MT
01/25Merck Announces Second-Quarter 2022 Dividend
BU
01/25Merck Declares Divined for the First Quarter of 2022, Payable on April 7, 2022
CI
01/24Britain to Start Testing Merck & Co.'s COVID-19 Antiviral Drug
MT
01/24Egypt Clears Merck & Co.'s COVID-19 Pill For Emergency Use
MT
01/24US FDA Declines Approval For Merck &Co.'s New Cough Drug, Seeks Further Information
MT
01/24FDA Declines to Approve Merck's Investigational Cough Treatment Gefapixant
MT
01/24MERCK : FDA Rejects Gefapixant Application, Requests More Data
DJ
01/24Merck Provides U.S. and Japan Regulatory Update for Gefapixant
BU
01/24Merck Provides U.S. and Japan Regulatory Update for Gefapixant
CI
More most relevant news
All news about MERCK & CO., INC.
06:46aMerck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine..
BU
01/27Merck & Co.'s Keytruda Wins EU Nod for Adjuvant Treatment of Kidney Cancer
MT
01/27Merck Gets EU Expanded OK for Keytruda in Some Kidney Cancer Patients
DJ
01/27Merck's Keytruda Gets EU Nod for Use as Adjuvant Therapy in Renal Cell Carcinoma
MT
01/27European Commission Approves Merck's KEYTRUDA« (pembrolizumab) as Adjuvant Therapy for ..
BU
01/26Vaccinex Says Two Patients Showed Complete Response in Study of Combo Drug Treatment fo..
MT
01/25Merck & Co. Declares Q2 Dividend of $0.69, Payable April 7 to Shareholders of Record Ma..
MT
01/25Merck Announces Second-Quarter 2022 Dividend
BU
01/25Merck Declares Divined for the First Quarter of 2022, Payable on April 7, 2022
CI
01/24Britain to Start Testing Merck & Co.'s COVID-19 Antiviral Drug
MT
More news
News in other languages on MERCK & CO., INC.
01/27Keytruda de Merck & Co. reçoit le feu vert de l'UE pour le traitement adjuvant du cance..
01/27MERCK : l'UE approuve le Keytruda pour le cancer du rein
01/27Merck & Co erhält erweitere EU-Zulassung für Keytruda bei Nierenkrebs
01/27Keytruda de Merck reçoit le feu vert de l'UE pour être utilisé comme traitement adjuvan..
01/26Vaccinex déclare que deux patients ont présenté une réponse complète dans une étude sur..
01/25Merck déclare un dividende pour le premier trimestre de 2022, payable le 7 avril 2022
01/24La Grande-Bretagne va commencer à tester le médicament antiviral COVID-19 de Merck & Co..
01/24L'Égypte autorise la pilule COVID-19 de Merck & Co pour une utilisation d'urgence
01/24L'autorité européenne de réglementation des médicaments se prononcera sur l'autorisatio..
01/24La FDA américaine refuse d'approuver le nouveau médicament contre la toux de Merck &Co...
More news
Analyst Recommendations on MERCK & CO., INC.
2021Daiwa Securities Starts Merck & Co. at Neutral With $70 Price Target
MT
2021ANALYST RECOMMENDATIONS : AT&T, BioNTech, Columbia Sports, Jefferies, Under Armour...
2021UBS Downgrades Merck & Co. to Neutral from Buy, Adjusts Price Target to $76 from $98
MT
2021Wells Fargo Starts Merck at Overweight With $90 Price Target
MT
2021Guggenheim Downgrades Merck to Neutral From Buy
MT
More recommendations
Press releases
06:46aMerck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine..
BU
01/27European Commission Approves Merck's KEYTRUDA« (pembrolizumab) as Adjuvant Therapy for ..
BU
01/25Merck Announces Second-Quarter 2022 Dividend
BU
01/24Merck Provides U.S. and Japan Regulatory Update for Gefapixant
BU
01/21Strides and its African subsidiary Universal Corporation partner with Medicines Patent
AQ
More press releases
Upcoming event on MERCK & CO., INC.